ECSP20060179A - DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Google Patents
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPIONInfo
- Publication number
- ECSP20060179A ECSP20060179A ECSENADI202060179A ECDI202060179A ECSP20060179A EC SP20060179 A ECSP20060179 A EC SP20060179A EC SENADI202060179 A ECSENADI202060179 A EC SENADI202060179A EC DI202060179 A ECDI202060179 A EC DI202060179A EC SP20060179 A ECSP20060179 A EC SP20060179A
- Authority
- EC
- Ecuador
- Prior art keywords
- bupropion
- dosage forms
- enantiomerically enriched
- methods
- pure bupropion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente descripción se describen formas de dosificación de (S)-bupropión enriquecido enantioméricamente o (R)-bupropión enriquecido enantioméricamente. El (S)-bupropión o (R)-bupropión puede estar enriquecido con deuterio o pueden tener una abundancia isotópica natural. Estas formas de dosificación pueden administrarse, con la alimentación o en ayunas, para tratar una afección mencionada en la presente descripción, para lograr un cierto parámetro farmacocinético de un bupropión o un metabolito de un bupropión, y/o para mejorar los niveles plasmáticos de dextrometorfano.In the present description, dosage forms of enantiomerically enriched (S) -bupropion or enantiomerically enriched (R) -bupropion are described. The (S) -bupropion or (R) -bupropion may be deuterium-enriched or may have a natural isotopic abundance. These dosage forms can be administered, with food or fasting, to treat a condition mentioned in the present description, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and / or to improve plasma levels of dextromethorphan. .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20060179A true ECSP20060179A (en) | 2020-12-31 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202060179A ECSP20060179A (en) | 2018-02-23 | 2020-09-23 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (en) |
| JP (3) | JP2021513998A (en) |
| KR (3) | KR20240091043A (en) |
| CN (2) | CN120827545A (en) |
| AU (3) | AU2019223187B2 (en) |
| BR (1) | BR112020017179A2 (en) |
| CA (1) | CA3092076A1 (en) |
| CL (1) | CL2020002166A1 (en) |
| CR (1) | CR20200415A (en) |
| EC (1) | ECSP20060179A (en) |
| IL (2) | IL276871B2 (en) |
| MA (1) | MA51914A (en) |
| MX (2) | MX2020008704A (en) |
| MY (1) | MY202993A (en) |
| NI (1) | NI202000056A (en) |
| NZ (1) | NZ767378A (en) |
| PE (1) | PE20211752A1 (en) |
| SG (1) | SG11202008056SA (en) |
| WO (1) | WO2019165379A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276871B2 (en) * | 2018-02-23 | 2024-11-01 | Axsome Therapeutics Inc | Pure bupropion dosage forms and methods for enantiomeric distortion purposes |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| WO2021055124A1 (en) * | 2019-09-20 | 2021-03-25 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| WO2025259728A1 (en) * | 2024-06-13 | 2025-12-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1051166A1 (en) * | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+) -bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| WO2005016318A1 (en) * | 2003-08-08 | 2005-02-24 | Biovail Laboratories Inc. | Modified-release tablet of bupropion hydrochloride |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| IL276871B2 (en) * | 2018-02-23 | 2024-11-01 | Axsome Therapeutics Inc | Pure bupropion dosage forms and methods for enantiomeric distortion purposes |
-
2019
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/en not_active Ceased
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/en not_active Application Discontinuation
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/en not_active Ceased
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/en active Pending
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/en active Pending
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/en active Pending
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/en not_active Ceased
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/en unknown
- 2019-02-25 CR CR20200415A patent/CR20200415A/en unknown
- 2019-02-25 MA MA051914A patent/MA51914A/en unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/en unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/en unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/en unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/en unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/en unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/en active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/en active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210003091A (en) | 2021-01-11 |
| IL276871B1 (en) | 2024-07-01 |
| CR20200415A (en) | 2021-02-03 |
| IL276871B2 (en) | 2024-11-01 |
| CN120827545A (en) | 2025-10-24 |
| AU2019223187B2 (en) | 2022-07-28 |
| CL2020002166A1 (en) | 2020-10-23 |
| JP2022153638A (en) | 2022-10-12 |
| IL276871A (en) | 2020-10-29 |
| IL313368A (en) | 2024-08-01 |
| EP3755312A4 (en) | 2022-03-16 |
| NI202000056A (en) | 2021-01-11 |
| AU2019223187A1 (en) | 2020-09-17 |
| JP2021513998A (en) | 2021-06-03 |
| CA3092076A1 (en) | 2019-08-29 |
| JP2024075655A (en) | 2024-06-04 |
| KR20240091043A (en) | 2024-06-21 |
| CN112087999A (en) | 2020-12-15 |
| BR112020017179A2 (en) | 2020-12-22 |
| WO2019165379A1 (en) | 2019-08-29 |
| SG11202008056SA (en) | 2020-09-29 |
| MA51914A (en) | 2020-12-30 |
| AU2022204521A1 (en) | 2022-07-21 |
| AU2022204521B2 (en) | 2024-09-05 |
| MX2023009281A (en) | 2023-08-17 |
| KR20230075531A (en) | 2023-05-31 |
| AU2024205858A1 (en) | 2024-09-05 |
| NZ767378A (en) | 2024-03-22 |
| EP3755312A1 (en) | 2020-12-30 |
| PE20211752A1 (en) | 2021-09-06 |
| MX2020008704A (en) | 2020-12-07 |
| MY202993A (en) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20060179A (en) | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | |
| MX2016010235A (en) | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor. | |
| UY32388A (en) | SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES AMLODIPINE AND LOSARTAN WITH IMPROVED STABILITY | |
| MX394496B (en) | Administration of Berberine Metabolites | |
| ECSP18015616A (en) | TABLET | |
| CL2016002560A1 (en) | Oral solid pharmaceutical dosage form comprising siponimod, a moisture protective agent and optionally a pharmaceutical excipient; Preparation procedure | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| UY35988A (en) | PROCESS FOR THE PRODUCTION OF AN INJECTABLE LOW CONCENTRATION NORADRENALINE SOLUTION | |
| CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
| CL2021001636A1 (en) | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | |
| MX2016014740A (en) | A METHOD FOR THE TREATMENT OF MOVEMENT DISORDERS WITH BEFIRADOL. | |
| MX2022004449A (en) | DOSAGE AND USES OF ORNITINE PHENYLCACETATE FOR THE TREATMENT OF HYPERAMONEMIA. | |
| UY29845A1 (en) | OSMOTE DOSAGE FORM WITH ASPECTS OF CONTROLLED RELEASE AND QUICK RELEASE | |
| BR112018074434A2 (en) | pharmaceutical compositions comprising safinamide | |
| ECSP22030119A (en) | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | |
| MX381450B (en) | A combination medicine comprising phenylephrine and paracetamol | |
| CO2018013792A2 (en) | Dosing regimens of vortioxetine for the rapid onset of the antidepressant effect | |
| MY203254A (en) | Pharmaceutical preparation | |
| MX2018010367A (en) | TITULATION OF CEBRANOPADOL. | |
| Kistanova | Genre Of Ode in 17–18th Centuries English Poets ‘Theoretical Reflection (A. Cowley, W. Congreve, E. Young) | |
| HK40068404A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| CO2019008347A2 (en) | Quick release composition of cinitapride and simethicone and process to prepare it | |
| HK40041795A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| CR20190401A (en) | DROPROPIZIN IN COMBINATION WITH AMBROXOL IN THE PHARMACEUTICAL FORM OF SYRUP AND TABLETS | |
| IN2014MU00190A (en) |